Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 8/20 | 0.60 |
| ▸ | GAA | P10253 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197087 | 1.00 | MAPT (0.60) | MAPTKMT2AMEN1GAALMNA | |
| SCHEMBL430787 | 1.00 | MAPT (0.60) | MAPTKMT2AMEN1GAALMNA | |
| SCHEMBL430878 | 0.86 | MAPT (0.62) | MAPTKMT2AMEN1GAALMNA | |
| SCHEMBL10196618 | 0.86 | MAPT (0.62) | MAPTKMT2AMEN1GAALMNA | |
| SCHEMBL430879 | 0.86 | MAPT (0.62) | MAPTKMT2AMEN1GAALMNA | |
| SCHEMBL426269 | 0.81 | MAPT (0.68) | MAPTKMT2AMEN1GAALMNA | |
| SCHEMBL426270 | 0.81 | MAPT (0.68) | MAPTKMT2AMEN1GAALMNA | |
| SCHEMBL10196633 | 0.81 | MAPT (0.68) | MAPTKMT2AMEN1GAALMNA | |
| SCHEMBL10196630 | 0.79 | MAPT (0.64) | MAPTKMT2AMEN1GAALMNA | |
| SCHEMBL3088439 | 0.79 | MAPT (0.62) | MAPTKMT2AMEN1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-7045517-B2 | Used to treat disorders associated with interleukin-12 overproduction; antiarthritic, antidiabetics; treating sepsis, Crohn's disease, multiple sclerosis, or psoriasis | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20060069090-A1 | Triazine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-03-30 | — | — | US | disclosed |
| US-20040053926-A1 | Triazine compounds | SYNTA PHARMACEUTICALS CORP., A DELAWARE CORPORATION | 2004-03-18 | — | — | US | disclosed |
| US-6680315-B2 | COMPOUNDS THAT DOWN-REGULATE INTERLEUKIN-12 PRODUCTION USED FOR TREATING INFLAMMATORY DISEASES: RHEUMATOID ARTHRITIS, SEPSIS, CHROHN'S DISEASE, MULTIPLE SCLEROSIS, PSORIASIS OR INSULIN-DEPENDENT DIABETES | SYNTA PHARMACEUTICALS CORP. | 2004-01-20 | — | — | US | disclosed |
| US-20020082259-A1 | Triazine compounds | SYNTA PHARMACEUTICALS CORP. | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | MAPT 238/4885KMT2A 4300/4885MEN1 4796/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MAPT 4316/4885KMT2A 1509/4885MEN1 3751/4885 |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | MAPT 1747/4885KMT2A 2431/4885MEN1 149/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | MAPT 1747/4885KMT2A 2431/4885MEN1 149/4885 |
| US-20020082259-A1 | Triazine compounds | CBR1, CBR3, SCO2 | MAPT 3970/4885KMT2A 2009/4885MEN1 4394/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | MAPT 2815/4885KMT2A 1939/4885MEN1 293/4885 |
| US-20040053926-A1 | Triazine compounds | CBR1, CBR3, SCO2 | MAPT 3970/4885KMT2A 2009/4885MEN1 4394/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | MAPT 4316/4885KMT2A 1509/4885MEN1 3751/4885 |
| US-20060069090-A1 | Triazine compounds | SCO2, NOXO1, NR2C2 | MAPT 4463/4885KMT2A 3110/4885MEN1 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.